<DOC>
	<DOC>NCT00177554</DOC>
	<brief_summary>The purpose of this study is to determine the complete response rate when CHOP-R chemotherapy in followed by Zevalin in previous untreated patients with follicular lymphoma</brief_summary>
	<brief_title>Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma</brief_title>
	<detailed_description>Patients with follicular lymphoma who require therapy and have been previously untreated are eligible for this non-randomized, phase II study evaluating up front therapy with CHOP-R x 3 cycles followed by zevalin and 4 additional weeks of rituxan.The complete response will be determined by combining IWC criteria and PET scanning.Secondary objectives include PET-CT conversion rate, frequency and severity of adverse events, duration of complete remission and time to next lymphoma therapy.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Conformed diagnosis of follicular lymphoma, grades 1,2 or 3 No prior chemotherapy No prior monoclonal antibody therapy Bulky or symptomatic disease, stage IIIV Performance status 02 Impaired bone marrow reserve Presence of CNS lymphoma Serious nonmalignant disease or active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Non-Hodgkin Lymphoma</keyword>
</DOC>